Home » Stocks » COGT

Cogent Biosciences, Inc. (COGT)

Stock Price: $8.50 USD -0.58 (-6.39%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 316.15M
Revenue (ttm) 7.87M
Net Income (ttm) -179.21M
Shares Out 37.19M
EPS (ttm) -16.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $8.50
Previous Close $9.08
Change ($) -0.58
Change (%) -6.39%
Day's Open 9.10
Day's Range 8.32 - 9.25
Day's Volume 434,524
52-Week Range 0.36 - 14.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOULDER, Colo. and CAMBRIDGE, Mass.

1 week ago - PRNewsWire

Cogent Biosciences, Inc. (COGT) delivered earnings and revenue surprises of -1910.00% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for th...

1 month ago - Zacks Investment Research

CAMBRIDGE, Mass., March 16, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announ...

1 month ago - PRNewsWire

CAMBRIDGE, Mass., Feb. 22, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

1 month ago - PRNewsWire

CAMBRIDGE, Mass., Feb. 18, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

2 months ago - PRNewsWire

CAMBRIDGE, Mass., Feb. 11, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

2 months ago - PRNewsWire

CAMBRIDGE, Mass., Dec. 4, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, tod...

4 months ago - PRNewsWire

CAMBRIDGE, Mass., Dec. 1, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announce...

4 months ago - PRNewsWire

CAMBRIDGE, Mass., Nov. 30, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

4 months ago - PRNewsWire

CAMBRIDGE, Mass., Nov. 20, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

4 months ago - PRNewsWire

CAMBRIDGE, Mass., Nov. 12, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

5 months ago - PRNewsWire

CAMBRIDGE, Mass., Oct. 26, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, to...

5 months ago - PRNewsWire

CAMBRIDGE, Mass., Oct. 5, 2020 /PRNewswire/ -- Unum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biotechnology company focused on developing precision therapies for genetically defined diseases, today a...

Other stocks mentioned: UMRX
6 months ago - PRNewsWire

Is (UMRX) Outperforming Other Medical Stocks This Year?

Other stocks mentioned: UMRX
7 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Aug. 31, 2020 /PRNewswire/ -- Unum Therapeutics Inc.

Other stocks mentioned: UMRX
7 months ago - PRNewsWire

CAMBRIDGE, Mass., Aug. 11, 2020 /PRNewswire/ -- Unum Therapeutics Inc.

Other stocks mentioned: UMRX
8 months ago - PRNewsWire

On Aug 6, the Nasdaq Composite Index topped the milestone of 11,000. The tech-heavy laden completed its 1000-point journey in 40 trading days, representing the fastest ever rise in 20 years.

Other stocks mentioned: KOPN, NVAX, QDEL, UMRX, VERI
8 months ago - Zacks Investment Research

Is (UMRX) Outperforming Other Medical Stocks This Year?

Other stocks mentioned: UMRX
8 months ago - Zacks Investment Research

Unum Therapeutics Inc. (UMRX) closed the most recent trading day at $2.74, moving +1.86% from the previous trading session.

Other stocks mentioned: UMRX
8 months ago - Zacks Investment Research

PHILADELPHIA, July 21, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Unum Therapeutics Inc. (NASDAQ: UMRX) ("Unum" or the "Company") on behalf of the Company's investors.

Other stocks mentioned: UMRX
8 months ago - PRNewsWire

Top Ranked Momentum Stocks to Buy for July 17th

Other stocks mentioned: MXIM, TMO, UMRX
9 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for July 10th

Other stocks mentioned: BSIG, NLS, PCRX, UMRX
9 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Unum Therapeutics Inc. (UMRX).

Other stocks mentioned: UMRX
9 months ago - Zacks Investment Research

Unum Therapeutics (UMRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Other stocks mentioned: UMRX
9 months ago - Zacks Investment Research

Unum Therapeutics (UMRX) stock is on the rise Tuesday following the acquisition of private biotechnology company Kiq on Monday. The post Unum Therapeutics: Why UMRX Stock Is Shooting 7% Higher Today app...

Other stocks mentioned: UMRX
9 months ago - InvestorPlace

CAMBRIDGE, Mass. and PHILADELPHIA, July 6, 2020 /PRNewswire/ -- Unum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biopharmaceutical company focused on developing therapies for solid tumors, today announ...

Other stocks mentioned: UMRX
9 months ago - PRNewsWire

Unum Therapeutics Inc (UMRX) delivered earnings and revenue surprises of 39.39% and 134.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Other stocks mentioned: UMRX
11 months ago - Zacks Investment Research

During Unum Therapeutics' (UMRX) upcoming Q1 earnings call, investor focus will be on the company's progress pertaining to its preclinical program, BOXR1030, for treating solid tumor cancers.

Other stocks mentioned: UMRX
11 months ago - Zacks Investment Research

Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of 120.00% and 271.07%, respectively, for the quarter ended December 2019.

Other stocks mentioned: UMRX
1 year ago - Zacks Investment Research

CAMBRIDGE, Mass., March 20, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced ...

Other stocks mentioned: UMRX
1 year ago - GlobeNewsWire

Unum Therapeutics Inc. (UMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Other stocks mentioned: UMRX
1 year ago - Zacks Investment Research

BOXR1030 is a GPC3-targeted CAR T cell incorporating the novel GOT2 transgene designed to improve T cell function in the solid tumor microenvironment by enhancing T cell metabolism

Other stocks mentioned: UMRX
1 year ago - GlobeNewsWire

-Cohort 1 enrollment is complete with no dose-limiting toxicities observed-

Other stocks mentioned: UMRX
1 year ago - GlobeNewsWire

-Clinical response and safety data with ACTR707 provide proof-of-mechanism for the ACTR platform and support the ongoing Phase 1 dose-escalation trial in relapsed or refractory NHL- -Clinical response a...

Other stocks mentioned: UMRX
1 year ago - GlobeNewsWire

Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of -25.81% and -76.87%, respectively, for the quarter ended September 2019.

Other stocks mentioned: UMRX
1 year ago - Zacks Investment Research

Unum Therapeutics Inc. (UMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Other stocks mentioned: UMRX
1 year ago - Zacks Investment Research

CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today an...

Other stocks mentioned: UMRX
1 year ago - GlobeNewsWire

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Unum (UNM) have what it takes?

Other stocks mentioned: UMRX
1 year ago - Zacks Investment Research

CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today a...

Other stocks mentioned: UMRX
1 year ago - GlobeNewsWire

Unum (UNM) reported earnings 30 days ago. What's next for the stock?

Other stocks mentioned: UMRX
1 year ago - Zacks Investment Research

CAMBRIDGE, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today an...

Other stocks mentioned: UMRX
1 year ago - GlobeNewsWire

Unum Therapeutics Inc. (UMRX) CEO Chuck Wilson on Q2 2019 - Earnings Call Transcript

Other stocks mentioned: UMRX
1 year ago - Seeking Alpha

Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of 12.82% and 1.36%, respectively, for the quarter ended June 2019.

Other stocks mentioned: UMRX
1 year ago - Zacks Investment Research

Unum Group (UNM) CEO Richard McKenney on Q2 2019 Results - Earnings Call Transcript

Other stocks mentioned: UMRX, UNM
1 year ago - Seeking Alpha

Unum (UNM) delivered earnings and revenue surprises of 1.49% and 1.22%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Other stocks mentioned: UMRX
1 year ago - Zacks Investment Research

Unum (UNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Other stocks mentioned: UMRX
1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Unum Therapeutics.

Other stocks mentioned: UMRX
1 year ago - Zacks Investment Research

Unum Therapeutics Inc (NASDAQ: UMRX) shares were under pressure Wednesday following a clinical trial update provided by the company late Tuesday.

Other stocks mentioned: UMRX
1 year ago - Benzinga

Shares of Unum Therapeutics Inc. tumbled 19% toward a record low in premarket trading Wednesday, after the Food and Drug Administration placed a "clinical hold" on the phase 1 trial of its cancer treatm...

Other stocks mentioned: UMRX
1 year ago - Market Watch

Unum Therapeutics Inc.'s (UMRX) CEO Chuck Wilson on Q1 2019 Results - Earnings Call Transcript

Other stocks mentioned: UMRX
1 year ago - Seeking Alpha

About COGT

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and ... [Read more...]

Industry
Biotechnology
IPO Date
Mar 29, 2018
Stock Exchange
NASDAQ
Ticker Symbol
COGT
Full Company Profile

Financial Performance

In 2020, COGT's revenue was $7.87 million, a decrease of -65.02% compared to the previous year's $22.50 million. Losses were -$179.21 million, 463.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for COGT stock is "Strong Buy." The 12-month stock price forecast is 20.67, which is an increase of 143.18% from the latest price.

Price Target
$20.67
(143.18% upside)
Analyst Consensus: Strong Buy